Strengthening the Existing Business and Expanding into New Business Areas

「To adapt to this challenging business environment, the drug discovery support business will streamline operations through the reorganization of Group companies and strengthen the provision of high-value-added services that can differentiate the Group from other companies. In the investment and consulting business, the Company will also seek out investments in the business succession and revitalization fields to strengthen and diversify the Group's earnings base.」

「There were no material changes during the interim consolidated accounting period.」

「There were no material changes to the management policy or management strategy established by our Group during the nine months ended December 31.」

「There have been no material changes during the cumulative second quarter of the current fiscal year.」

「There were no material changes to the management policy or management strategy established by our Group during the nine months ended December 31.」

「There were no material changes during the cumulative consolidated period through the first quarter to the objective indicators and other measures used to assess progress toward the Company's management objectives.」

「There were no material changes to the management policy or management strategy established by our Group during the nine months ended December 31.」

「There have been no material changes to the management policy or strategy established by our Group during the second quarter of the current consolidated cumulative period.」

「Building on the results achieved over the past 4 years, we intend to steadily implement the following measures over the next 4 years to further strengthen and expand our business platform. Against the backdrop of increased consolidated business earnings and a stronger financial base, in the drug discovery support business we will strengthen capital investment to expand existing services and introduce new services, while strengthening the research and development activities supporting the establishment of a highly profitable business.」

「To achieve sustained growth in corporate value, we believe that we must work to further strengthen our existing businesses while seeking to enter new businesses beyond our current business scope.」

「In the ＴＧＢＳ business, the Company worked to procure popular products in its e-commerce business and focused on expanding sales channels through platforms, meaning major online shopping sites, to mitigate the expected impact of a decline in sales following the consumption tax rate increase. In the “Other” business within the ＴＧＢＳ business, it strengthened its efforts in business succession consulting.」

「In the ＴＧＢＳ business, the Company worked to procure popular products in its e-commerce business and focused on expanding sales channels through platforms, meaning major online shopping sites. Outside the e-commerce business, it strengthened its efforts in business succession consulting.」

「To achieve sustained growth in corporate value, we believe that we must work to further strengthen our existing businesses while seeking to enter new businesses beyond our current business scope.」

「In the CRO business, the Company worked to strengthen orders by expanding and deepening transactions with existing customers while focusing on developing new customers. To further increase orders for nonclinical studies and meet the diverse needs of customers, mainly pharmaceutical companies, it began selling new disease models, including “biological stress visualization mice” and “atopic dermatitis model mice,” further expanded its lineup, and worked to use model mice in nonclinical studies, including through a business alliance with 京ダイアグノスティクス株式会社, which produces PDSX for use in nonclinical studies.」

「In the CRO business, the Company worked to strengthen orders by expanding and deepening transactions with existing customers while focusing on developing new customers. To further increase orders for nonclinical studies and meet the diverse needs of customers, mainly pharmaceutical companies, 株式会社トランスジェニック began selling new disease models, including “biological stress visualization mice” and “atopic dermatitis model mice,” further expanded its lineup, and worked to use model mice in nonclinical studies.」

「On 1 April of the current year, the Company's consolidated subsidiary 株式会社安評センター acquired the business of 公益財団法人食品農医薬品安全性評価センター. As a result, CRO business order backlog at the end of the first quarter of the current consolidated fiscal year increased substantially to ¥1,209 million, up 182.4% year on year, and its capacity to accept orders for nonclinical safety studies across a broad range of fields also expanded significantly.」

「As part of its initiatives in new businesses, the Company established 株式会社ＴＧビジネスサービス in November of the previous year to provide advisory and support services relating to business succession and business revitalization across a broad range of fields, as well as to conduct M&A.」

「The Company also entered into license agreements for APPOSK mice as an Alzheimer's disease model, wild-type TAU transgenic mice, and mental and neurological disease model mice, and expanded its lineup of central nervous system model mice, which are in strong demand. In addition, it entered into a joint research and development agreement with its capital and business alliance partner 株式会社免疫生物研究所 to develop an Alzheimer's disease treatment through preclinical studies using the above-mentioned APPOSK mice and antibodies owned by that company.」

「The Company also entered into a license agreement with Osaka City University and Specially Appointed Professor 森 啓 (森 啓) and expanded its lineup of central nervous system model mice, which are in strong demand. In addition, it entered into a joint research and development agreement with its capital and business alliance partner 株式会社免疫生物研究所 to develop an Alzheimer's disease treatment through preclinical studies using the above-mentioned APPOSK mice and antibodies owned by that company.」

「We believe that we must work to further strengthen our existing businesses while seeking to enter new businesses beyond our current business scope.」

「As part of its initiatives in new businesses, on 20 April of the previous year the Company resolved to, and did, subscribe jointly with its capital and business alliance partner 株式会社免疫生物研究所 for a third-party allotment of new shares conducted by that company, with a payment date of 11 May, in order to promote the practical application as an antibody drug of the anti-HIV antibody owned by ㈱CURED (Yokohama; research and development of antibody drugs).」

「As part of its initiatives in new businesses, on 20 April of the current year the Company resolved to, and did, subscribe jointly with its capital and business alliance partner 株式会社免疫生物研究所 for a third-party allotment of new shares conducted by that company, with a payment date of 11 May, in order to promote the practical application as an antibody drug of the anti-HIV antibody owned by ㈱CURED (Yokohama; research and development of antibody drugs).」

「As part of its initiatives in new businesses, on 20 April of the current year the Company resolved to, and did, subscribe jointly with its capital and business alliance partner 株式会社免疫生物研究所 for a third-party allotment of new shares conducted by that company, with a payment date of 11 May, in order to promote the practical application as an antibody drug of the anti-HIV antibody owned by ㈱CURED (Yokohama; research and development of antibody drugs).」

「To realize our management philosophy, we believe that we must work to further strengthen our existing businesses while seeking to enter new businesses beyond our current business scope.」